Subscribe

Receive updates about our latest products in your inbox

Register For Our Next Webinar

Rewiring the Brain for Weight Loss

About Us

For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional

Search the Blog

  • There are no suggestions because the search field is empty.

IBD Management & SBI

iStock-1189299527A retrospective case series review of people with Crohn’s disease (CD) and ulcerative colitis (UC) whose symptoms weren’t controlled by traditional pharmaceutical therapies showed a symptom improvement rate of 76% after 12 weeks of taking serum-derived bovine immunoglobulin (SBI).

Crohn’s disease is a relapsing, chronic, systemic, transmural inflammatory condition that can involve the entire gastrointestinal tract. Symptoms can be very varied, even including fever, mouth sores, and inflammation in the joints, skin, eyes, bile ducts and liver. Ulcerative colitis, on the other hand, can be transmural in later stages, but tends to affect the mucosa only, leading to systemic symptoms such as rectal tenesmus, which is the sensation of incomplete evacuation of the bowel. Clinically, SBI has been shown to reduce many of the symptoms of irritable bowel syndrome with diarrhea (IBD-D) previous to this study. Case studies have also been able to identify multiple benefits of SBI in drug-refractory IBS-D patients, including endoscopic remission, yet further exploration in human subjects is needed to confirm the types of benefits for the CD and UC patient population.

This study explored symptoms management in IBD patients over 12 weeks using a Likert scale and regression model following 5 grams SBI per day for nutritional support. 

The odds ratio from the regression model demonstrated that the patients were 2.8 times more likely to report improvements in symptoms when taking the SBI (those improvements were not significantly related to gender, race or disease state). What’s more, the improvements increased steadily between weeks 1 and 12. Forty-nine percent of the cases reported a positive response to the therapy during the first week. By week 12, 76% had seen an improvement in their symptoms.

The scientists behind the study suggest that SBI should be considered for use in the nutritional support of IBD regardless of disease location, phenotype, duration, activity or complexity.

Submit your comment

Related Post

SBI Cost Savings for IBD Patients

A pilot study has provided evidence of the cost-saving benefits of the incorporation of serum-derived bovine immunoglobu...

Learn more

Pouchitis & SBI

Compelling research has shown positive outcomes for patients suffering from pouchitis using Serum-Derived Bovine Immunog...

Learn more

IBS Case Responses to SBI

A case series of 10 patients with long-standing, symptomatic, intractable drug-refractory irritable bowel syndrome (IBS)...

Learn more